Last reviewed · How we verify
NCT03872830
A Phase Ⅱ Clinical Study Trial of Felbinac Trometamol Injection in China
Phase 2 trial testing Felbinac Trometamol Injection in Pain in 165 participants. Completed in 5 December 2019.
30 September 2019
Quick facts
| Lead sponsor | Shijiazhuang Yiling Pharmaceutical Co. Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 165 |
| Start date | 27 March 2019 |
| Primary completion | 30 September 2019 |
| Estimated completion | 5 December 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Felbinac Trometamol Injection — full drug profile →
- Placebos — full drug profile →
Conditions studied
- Pain — all drugs for Pain →
Sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multicenter, randomized, double-blind, placebo-controlled, dose-exploratory phase II clinical trial to evaluating the efficacy and safety of Felbinac Trometamol Injection in the treatment of moderate to severe pain after surgery.Main purpose is preliminary evaluation the effectiveness of Felbinac Trometamol Injection in the treatment of moderate and severe pain after surgery.Secondary purpose is to explore the dosage regimen of Felbinac Trometamol Injection in the treatment of moderate and severe pain after surgery, and provide data support for later clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03872830
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Felbinac Trometamol Injection
Trials testing the same drug.
- NCT05297669 — A Phase # Clinical Study Trial of Felbinac Trometamol Injection in China · Phase 3 · completed
- NCT04526132 — A Phase Ⅲ Clinical Study Trial of Felbinac Trometamol Injection in China · Phase 3 · completed
- NCT03617510 — A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China · Phase 1 · completed
- NCT03235778 — A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China · Phase 1 · completed
Other recruiting trials for Pain
Currently open trials in the same condition.
- NCT07533409 — Tactile and Pain Sensory Thresholds and Hand Grip Strength · recruiting
- NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
- NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting
Other Shijiazhuang Yiling Pharmaceutical Co. Ltd trials
Trials by the same sponsor.
- NCT06755944 — A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke · Phase 2, PHASE3 · enrolling by invitation
- NCT06823232 — A Study on the Substance Balance of [14C]XY0206 in Healthy Adult Chinese Men · Phase 1 · completed
- NCT05876832 — A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) · Phase 3 · not yet recruiting
- NCT05515393 — A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke · Phase 2 · unknown
- NCT05297669 — A Phase # Clinical Study Trial of Felbinac Trometamol Injection in China · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03872830 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shijiazhuang Yiling Pharmaceutical Co. Ltd
- Last refreshed: 7 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03872830.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing